NICOLA HANANIA to Eosinophils
This is a "connection" page, showing publications NICOLA HANANIA has written about Eosinophils.
Connection Strength
5.008
-
Persistent airway obstruction in severe eosinophilic asthma: targeting interleukin-5 and eosinophils. Eur Respir Rev. 2025 Oct; 34(178).
Score: 0.877
-
Response. Chest. 2019 12; 156(6):1276.
Score: 0.578
-
Immunological biomarkers in severe asthma. Semin Immunol. 2019 12; 46:101332.
Score: 0.576
-
Targeting IL-5 in COPD. Int J Chron Obstruct Pulmon Dis. 2019; 14:1045-1051.
Score: 0.556
-
Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2016 10; 4(10):781-796.
Score: 0.462
-
Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013 Apr 15; 187(8):804-11.
Score: 0.365
-
Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials. Lancet. 2026 May 23; 407(10543):2027-2039.
Score: 0.226
-
Impact of Sex on Prediction of Asthma Attacks by Clinical Risk Factors and Type 2 Biomarkers. Chest. 2026 Jun; 169(6):1464-1475.
Score: 0.221
-
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation. N Engl J Med. 2024 06 27; 390(24):2274-2283.
Score: 0.197
-
Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population. J Allergy Clin Immunol Pract. 2024 05; 12(5):1215-1224.e3.
Score: 0.193
-
Influence of baseline bronchodilator reversibility and blood eosinophils on lung function in patients with asthma following omalizumab. J Allergy Clin Immunol Pract. 2024 02; 12(2):512-514.e2.
Score: 0.191
-
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts. N Engl J Med. 2023 07 20; 389(3):205-214.
Score: 0.184
-
Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2025 Aug; 13(8):687-697.
Score: 0.053
-
Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials. Lancet Respir Med. 2025 Jun; 13(6):505-516.
Score: 0.052
-
Tezepelumab in patients with allergic and eosinophilic asthma. Allergy. 2024 05; 79(5):1134-1145.
Score: 0.048
-
Novel Anti-Inflammatory Approaches to COPD. Int J Chron Obstruct Pulmon Dis. 2023; 18:1333-1352.
Score: 0.046
-
Controversies in Allergy: Choosing a Biologic for Patients with Severe Asthma. J Allergy Clin Immunol Pract. 2022 02; 10(2):410-419.
Score: 0.042
-
How to Assess Effectiveness of Biologics for Asthma and What Steps to Take When There Is Not Benefit. J Allergy Clin Immunol Pract. 2021 03; 9(3):1081-1088.
Score: 0.039
-
Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2020 11; 125(5):565-576.e1.
Score: 0.037
-
Prospective, Single-Arm, Longitudinal Study of Biomarkers in Real-World Patients with Severe Asthma. J Allergy Clin Immunol Pract. 2020 09; 8(8):2630-2639.e6.
Score: 0.037
-
Assessing biomarkers in a real-world severe asthma study (ARIETTA). Respir Med. 2016 06; 115:7-12.
Score: 0.028